Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market By Disease Type (Benign Focal Amyotrophy of ALS, Infantile Spinal Muscular Atrophy, Juvenile Spinal Muscular Atrophy, Kugelberg-Welander Disease, Primary Lateral Sclerosis, Progressive Bulbar Palsy, Spinal Muscular Atrophy, Upper Motor Neuron Disease, Werdnig-Hoffman Disease and Wohlfart-Disease), Drug Type (Riluzole, Edaravone (Radicava) and Others), Distribution Channel (Hospital Pharmacies, and Retail and Online Pharmacies), Treatment type (Chemotherapy and Stem Cell Therapy) End User (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028